ERB 257Alternative Names: ERB-257
Latest Information Update: 10 Aug 2009
At a glance
- Originator Wyeth
- Mechanism of Action Estrogen receptor beta agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 06 May 2009 ERB 257 is discontinued following completion of phase I trials (US and Japan)